Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference

Overview of CSL Behring Innovations in Recombinant Technologies Presented at International Conference

Melbourne, Australia — 20/05/2011

CSL Limited (ASX:CSL) subsidiary, CSL Behring, today issued a press release regarding advances that it is making in developing innovative new technologies to meet the unmet therapeutic needs of patients with haemophilia A and B. This will be the topic of an oral presentation at an international medical congress on 22 May 2011. A copy of this press release is available on the CSL Behring website and is included in the PDF below.


Download the full release:
PDF icon Recombinant Technologies (0.06MB)


Media:
Sharon McHale
Senior Director Public Affairs
Phone: +61 3 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au 


Sheila A. Burke
Director, Worldwide Commercial Public Relations and Communications
CSL Behring
1020 First Avenue
King of Prussia, PA 19406
+610 878 4209
Email: sheila.burke@cslbehring.com


Investors:
Mark Dehring
Head of Investor Relations
CSL Limited
Phone: +61 3 9389 2818
Email: mark.dehring@csl.com.au
© 2016 CSL Limited